Altaris Combines Kindeva Drug Delivery and Meridian Medical Technologies

Altaris Capital Partners Acquires Kindeva Drug Delivery from 3M

May 1, 2020

Medical Devices

Altaris Capital Partners has acquired Kindeva Drug Delivery L.P. (formerly 3M Drug Delivery Systems) from 3M Company for $650 million in a corporate carve-out transaction. Monroe Capital provided financing and an equity co-investment to support the deal, and 3M will retain a minority interest alongside Altaris as Kindeva operates independently to pursue growth and capital investments.

Kindeva Drug Delivery (Altaris) Acquires Summit Biosciences

January 18, 2024

Medical Devices

Kindeva Drug Delivery, an operating company of healthcare investor Altaris, has acquired Summit Biosciences from its founding family shareholders. The acquisition adds Summit’s FDA- and EMA-approved 55,000 sq. ft. cGMP intranasal CDMO facility in Lexington, Kentucky, expanding Kindeva’s nasal drug‑delivery platform and global manufacturing footprint.

Altaris Capital Partners Acquires Meridian Medical Technologies from Pfizer

December 30, 2021

Medical Devices

Altaris Capital Partners has entered into an agreement to acquire Meridian Medical Technologies from Pfizer. Meridian, a pioneer in emergency response drug-device combination products and auto-injectors with facilities in St. Louis, Missouri and Columbia, Maryland and more than 750 employees, will become an Altaris portfolio company to expand the firm's capabilities in medical countermeasures and emergency response solutions.

Altaris Acquires Minaris Regenerative Medicine from Resonac

September 23, 2024

Healthcare Services

Altaris, LLC has acquired Minaris Regenerative Medicine from Resonac Corporation, making Minaris a wholly owned portfolio company of Altaris. Minaris is a cell therapy CDMO with six facilities across the United States, Germany and Japan and more than 500 employees; the deal advances Altaris' strategic initiative to build capabilities in cell and gene therapy manufacturing.

Mercalis and PharmaCord Merge and Rebrand as Valeris

May 27, 2025

Healthcare Services

Mercalis and PharmaCord have completed their previously announced merger and rebranded the combined company as Valeris. The new, PE-backed (Permira and Odyssey Investment Partners) company will offer integrated commercialization services — including data & insights, patient support services, and HCP engagement tools — to life sciences customers.

Altaris Acquires WuXi AppTec's Advanced Therapies U.S. and U.K. Operations (including OXGENE)

December 24, 2024

Biotechnology

Altaris, a New York-based healthcare-focused investment firm, acquired the U.S. and U.K. operations of WuXi AppTec's Advanced Therapies unit (including OXGENE). Advanced Therapies will be renamed and headquartered in the United States and Altaris intends to combine it with its recently acquired Minaris Regenerative Medicine to form Minaris Advanced Therapies, expanding cell-therapy CDMO capabilities and global footprint.